TRODELVY Safety: Diarrhoea Management

SAFETY PROFILE
DISCONTINUATION RATES
NEUTROPENIA MANAGEMENT
DIARRHOEA MANAGEMENT

PRACTICAL AE MANAGEMENT WITH TRODELVY¹

Management of diarrhoea

Patients who exhibit an excessive cholinergic response to treatment with TRODELVY (e.g. abdominal cramping, diarrhoea, salivation, etc.) can receive appropriate treatment (e.g. atropine) for subsequent treatments with TRODELVY.¹

ABBREVIATIONS:

AE, adverse event.

REFERENCES:

1. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics, June 2025. 2. Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541. 3. Rugo H, et al. NPJ Breast Cancer. 2022; 8: 98.doi: 10.1038/s41523-022-00467-1.

TRODELVY

Safety

PRACTICAL AE MANAGEMENT WITH TRODELVY¹

Management of diarrhoea

ABBREVIATIONS:

REFERENCES:

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ

ΛΙΑΝΙΚΗ ΤΙΜΗ

PRACTICAL AE MANAGEMENT WITH TRODELVY1

Management of diarrhoea

IN THE ASCENT TRIAL TRODELVY GROUP,MOST INSTANCES OF DIARRHOEA OCCURRED WITHIN THE FIRST 2 CYCLES AND LASTED ABOUT 1 WEEK3

ABBREVIATIONS:

REFERENCES:

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ

ΛΙΑΝΙΚΗ ΤΙΜΗ

PRACTICAL AE MANAGEMENT WITH TRODELVY¹

IN THE ASCENT TRIAL TRODELVY GROUP,
MOST INSTANCES OF DIARRHOEA OCCURRED WITHIN THE FIRST 2 CYCLES AND LASTED ABOUT 1 WEEK³